Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Waters

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
Metabolism: Clinical and Experimental|November 20, 2018
High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)Kwok Leung Ong, Nicholas Hui, Andrzej S Januszewski, et al.
Circulation. Cardiovascular Genetics|December 3, 2011
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studiesBenoit J Arsenault, S Matthijs Boekholdt, G Kees Hovingh, et al.
American Heart Journal|February 23, 2020
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapibJean-Claude Tardif, Marie-Pierre Dubé, Marc A Pfeffer, et al.
Plos One|December 23, 2014
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Journal of the American College of Cardiology|December 28, 2010
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
The American Journal of Cardiology|August 8, 2009
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery diseaseOle Faergeman, Ingar Holme, Rana Fayyad, et al.
Journal of Clinical Lipidology|November 7, 2017
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular riskBenoit J Arsenault, Francine Petrides, Fatiha Tabet, et al.
Circulation. Genomic and Precision Medicine|April 2, 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular MedicineDavid Rhainds, Chris J Packard, Mathieu R Brodeur, et al.
JAMA|November 19, 2002
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trialDavid D Waters, Edwin L Alderman, Judith Hsia, et al.
The New England Journal of Medicine|March 24, 2006
Effect of ACAT inhibition on the progression of coronary atherosclerosisSteven E Nissen, E Murat Tuzcu, H Bryan Brewer, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
Metabolism: Clinical and Experimental|November 20, 2018
High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)Kwok Leung Ong, Nicholas Hui, Andrzej S Januszewski, et al.
Circulation. Cardiovascular Genetics|December 3, 2011
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studiesBenoit J Arsenault, S Matthijs Boekholdt, G Kees Hovingh, et al.
American Heart Journal|February 23, 2020
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapibJean-Claude Tardif, Marie-Pierre Dubé, Marc A Pfeffer, et al.
Plos One|December 23, 2014
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Journal of the American College of Cardiology|December 28, 2010
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
The American Journal of Cardiology|August 8, 2009
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery diseaseOle Faergeman, Ingar Holme, Rana Fayyad, et al.
Journal of Clinical Lipidology|November 7, 2017
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular riskBenoit J Arsenault, Francine Petrides, Fatiha Tabet, et al.
Circulation. Genomic and Precision Medicine|April 2, 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular MedicineDavid Rhainds, Chris J Packard, Mathieu R Brodeur, et al.
JAMA|November 19, 2002
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trialDavid D Waters, Edwin L Alderman, Judith Hsia, et al.
The New England Journal of Medicine|March 24, 2006
Effect of ACAT inhibition on the progression of coronary atherosclerosisSteven E Nissen, E Murat Tuzcu, H Bryan Brewer, et al.
Pageof 16